Trial Profile
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Oct 2020
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GEMELLI 1
- Sponsors Sanofi
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 18 Apr 2019 This trial has been completed in Finland, according to European Clinical Trials Database.
- 15 Feb 2019 Status changed from active, no longer recruiting to completed.